Vertex Pharmaceuticals Inc. (VRTX)

165.11
NASDAQ : Health Technology
Prev Close 166.67
Day Low/High 164.67 / 167.99
52 Wk Low/High 136.50 / 194.92
Avg Volume 1.27M
Exchange NASDAQ
Shares Outstanding 255.56M
Market Cap 42.59B
EPS 1.10
P/E Ratio 66.40
Div & Yield N.A. (N.A)
Stock Futures Up Slightly, Dollar Drifts as Jones Stuns Moore in Alabama

Stock Futures Up Slightly, Dollar Drifts as Jones Stuns Moore in Alabama

A surprise win for Democrat Doug Jones in Alabama's special Senate election has the dollar on the back foot and investors in a cautious mood ahead of the final Fed meeting of the year.

Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank

Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank

Deutsche Bank said "chances of a Vertex takeout are as good as at any point in the company's history."

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Growth is here to stay, and value is for more than just the old strongholds.

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as...

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO® (ivacaftor) In Children With Cystic Fibrosis Ages 1 To 2 Years

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO® (ivacaftor) In Children With Cystic Fibrosis Ages 1 To 2 Years

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from an open-label Phase 3 study of KALYDECO ® (ivacaftor) in children with cystic fibrosis (CF) ages 1 to 2 years who have one...

16 Amazing Stocks to Trade in This Unstoppable Bull Market

16 Amazing Stocks to Trade in This Unstoppable Bull Market

After a shortened trading week light on volume, the S&P 500 is losing some steam. But Fundstrat says index uptrends 'remain intact' moving toward the New Year.

Vertex Receives CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For The Treatment Of Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation In The European Union

Vertex Receives CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For The Treatment Of Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation In The European Union

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending extension of the Marketing...

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced presentations of data at the Annual North American Cystic Fibrosis Conference (NACFC), November 2 to 4, 2017, in Indianapolis, from across the...

Phase 3 Studies Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis Ages 12 And Older Published In The New England Journal Of Medicine

Phase 3 Studies Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis Ages 12 And Older Published In The New England Journal Of Medicine

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the New England Journal of Medicine (NEJM) published two articles with results from two Phase 3 studies of the tezacaftor/ivacaftor...

Vertex To Present At The Credit Suisse Healthcare Conference On November 7

Vertex To Present At The Credit Suisse Healthcare Conference On November 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.

Vertex Announces New $750,000 Program To Support The Work Of The Next Generation Of Cystic Fibrosis Researchers

Vertex Announces New $750,000 Program To Support The Work Of The Next Generation Of Cystic Fibrosis Researchers

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a new $750,000 program to support the work of young faculty who are newly establishing independent research programs in cystic fibrosis (CF).

Vertex Reports Third-Quarter 2017 Financial Results

Vertex Reports Third-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2017.

Vertex Doubles Scholarship Program To Support The Academic And Professional Advancement Of People Living With Cystic Fibrosis And Their Families

Vertex Doubles Scholarship Program To Support The Academic And Professional Advancement Of People Living With Cystic Fibrosis And Their Families

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.

Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a 10-year, $500 million corporate giving commitment focused on providing patient and caregiver support including access to our medicines; expanding our...

Vertex To Announce Third Quarter 2017 Financial Results On October 25

Vertex To Announce Third Quarter 2017 Financial Results On October 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close.

Vertex To Present At The Leerink Partners Roundtable Series On September 27

Vertex To Present At The Leerink Partners Roundtable Series On September 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.

Vertex Announces Upcoming Presentations Of Data At 2017 North American Cystic Fibrosis Conference

Vertex Announces Upcoming Presentations Of Data At 2017 North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis...

Vertex To Present At The Morgan Stanley Healthcare Conference On September 11

Vertex To Present At The Morgan Stanley Healthcare Conference On September 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Trade from the long side, but have a sell stop below $149 in case of a reversal.

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the acceptance of its applications for the use of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis (CF) ages 12 and...

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Investors, antsy about increased volatility in the markets, might look to high dividend yielding REITs to ride out the uncertainty.

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BA, CAI, CNHI, FFWM, FSV, NEP, NOW, TGI, TRK, TSU, WPG Downgrades: AAT, BLMN, FBR, GSK, HZO, QDEL, VRTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017.

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

TheStreet Quant Rating: B (Buy)